托珠单抗联合改善病情抗风湿药治疗中重度类风湿关节炎短期临床观察

doi:10.12092/j.issn.1009-2501.2018.12.012

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (12): 1386-1391.doi: 10.12092/j.issn.1009-2501.2018.12.012

托珠单抗联合改善病情抗风湿药治疗中重度类风湿关节炎短期临床观察

陈兰芳，强孚勇，徐亮

皖南医学院附属弋矶山医院风湿免疫科，芜湖 241001，安徽

收稿日期:2018-08-15 修回日期:2018-09-16 出版日期:2018-12-26 发布日期:2018-12-27
作者简介:陈兰芳，女，硕士，主治医师，研究方向：系统性红斑狼疮发病机制。 Tel: 18130347966 E-mail: chenlanfang2005@hotmail.com
基金资助:
安徽省卫生和计划生育委员会科研计划项目-全科医学临床科研课题（2016QK040）

Short-term clinical observation of moderate to severe active rheumatoid arthritis treated with tocilizumab combined with disease modifying antirheumatic drugs

CHEN Lanfang, QIANG Fuyong, XU Liang

Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2018-08-15 Revised:2018-09-16 Online:2018-12-26 Published:2018-12-27

摘要/Abstract

摘要：

目的: 研究托珠单抗联合改善病情抗风湿药（DMARDs）治疗中重度活动性类风湿关节炎（RA）12周临床疗效及不良反应。方法: 20例中重度活动的RA患者分别在0周、4周、8周接受托珠单抗8 mg/kg治疗，同时予以DMARDs治疗，在4周、8周、12周观察疗效及不良反应。观察指标为血沉、C反应蛋白（CRP）、类风湿因子（RF）、血红蛋白、血小板、疾病活动度评分（DAS28）、肝功能、肾功能、患者对疾病总体评价和医生对疾病总体评价及美国风湿病学会疗效评价指标（ACR20、ACR50）。结果: 与治疗前相比，20例RA患者在4周、8周、12周时血沉、CRP、RF、血小板均明显下降，差异均有统计学意义（P<0.01）；DAS28在治疗4周时明显改善，在治疗8周时进一步改善，差异均有统计学意义（P<0.01）；而血红蛋白在4周时明显上升，到12周时进一步上升，差异均有统计学差异（P<0.01）；患者和医生总体评价评分持续性下降，差异有统计学意义（P<0.01）；在8周和12周时达到ACR20者达90%、95%，达到ACR50者达80%、90%；20例患者中有1例出现上呼吸道感染，但无严重感染、肝肾损害及过敏反应发生。结论: 托珠单抗联合DMARDs治疗RA短期之内即改善患者的症状体征及炎症指标，且无明显不良反应发生。

关键词: 托珠单抗, 类风湿关节炎, 疗效

Abstract:

AIM: To study the clinical efficacy and adverse reactions of tocilizumab combined with disease modifying antirheumatic drugs (DMARDs) in the treatment of moderate-to-severe active rheumatoid arthritis (RA) for 12 weeks. METHODS: Twenty patients with moderate-to-severe active RA were treated with 8 mg/kg of tocilizumab at 0, 4th, and 8th week and treated with DMARDs. The effects and adverse reactions were observed at 4th week, 8th week and 12th week. The observed indicators were erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), hemoglobin, platelet, DAS28, hepatic function, renal function, ACR20, ACR50, overall evaluation of the patient and physician to disease. RESULTS: Compared with baseline, ESR, CRP, RF and platelet counts in 20 RA patients were significantly decreased at 4th week, 8th week, and 12th week, and the difference was statistically significant (P<0.01); DAS28 was significantly improved at 4th week of treatment, and further improved at 8th week of treatment, the difference was statistically significant (P<0.01); and hemoglobin increased significantly at 4th weeks, and further increased at 12th week, the difference was statistically significant (P<0.01). The overall evaluation scores of the patients and doctors decreased continuously, the difference was statistically significant (P<0.01); At 8th week and 12th week, ACR20 reached 90%, 95%, and ACR50 reached 80%, 90%; 1 of 20 patients appeared upper respiratory tract infection, there were no liver, kidney and hypersensitivity reactions. CONCLUSION: Tocilizumab combined with DMARDs in the treatment of RA within a short period of time improve the patient's symptoms, signs and inflammation indicators with no significant adverse reactions occurred.

Key words: tocilizumab, rheumatoid arthritis, clinical efficacy

中图分类号:

R593.22

陈兰芳，强孚勇，徐亮. 托珠单抗联合改善病情抗风湿药治疗中重度类风湿关节炎短期临床观察[J]. 中国临床药理学与治疗学, 2018, 23(12): 1386-1391.

CHEN Lanfang, QIANG Fuyong, XU Liang. Short-term clinical observation of moderate to severe active rheumatoid arthritis treated with tocilizumab combined with disease modifying antirheumatic drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1386-1391.

参考文献

［1］McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis［J］. N Engl J Med, 2011, 365(23): 2205-2219.
［2］杨红，林彬，杨宏, 等. 艾拉莫德对类风湿关节炎患者血管内皮生长因子及色素上皮衍生因子表达的影响［J］. 中国临床药理学与治疗学, 2017, 22 (1): 68-71.
［3］Buch MH. Defining refractory rheumatoid arthritis ［J］. Ann Rheum Dis, 2018, 77(7): 966-969.
［4］Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity［J］. Ann Rheum Dis, 1993, 52(3): 232-234.
［5］Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation ［J］. J Bone Miner Res, 1996, 11(1): 88-95.
［6］史群, 赵岩, 鲍春德, 等. 托珠单抗联合改善病情抗风湿药治疗类风湿关节炎的多中心、随机、双盲、安慰剂对照临床研究［J］. 中华内科杂志, 2013, 52(4): 323-329.
［7］Lin CT, Huang WN, Hsieh CW, et al. Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis- A three-year study in Taiwan［J］. J Microbiol Immunol Infect, 2017, 17(3): 1-10.
［8］Kremer JM, Blanco R, Halland AM, et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial ［J］. Clin Exp Rheumatol, 2016, 34(4): 625-633.
［9］Abdulkader OAF, Qushmaq K, Aljishi F. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor［J］. Ann Saudi Med, 2016, 36(3): 190-196.
［10］Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an antiinterleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled dose-escalation trial［J］. Arthritis Rheum, 2002, 46(12): 3143-3150.
［11］Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials［J］. Rheumatology, 2011, 50 (3): 552-562.
［12］姜楠, 费允云, 赵岩. 白细胞介素-6 阻断剂在类风湿关节炎的治疗应用［J］. 中华临床免疫和变态反应杂志, 2012, 6(3): 232-236.
［13］Schinnerling K, Aguillón JC, Catalán D, et al. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis ［J］. Clin Experimental Immunol, 2017, 189(1): 12-20.
［14］Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis ［J］. Expert Rev Clin Immunol, 2017, 13(6):535-551.
［15］Abu-Shakra M, Zisman D, Balbir-Gurman A, et al. Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis［J］. Isr Med Assoc J, 2018, 20(4): 239-244.
［16］孙丽君, 林玮, 闰永龙, 等. 难治性类风湿关节炎托珠单抗治疗临床观察［J］. 河北医药，2016, 38(24): 3758-3764.
［17］孙芳芳, 叶霜. 托珠单抗联合甲氨蝶呤治疗难治性类风湿关节炎的疗效观察［J］. 上海交通大学学报, 2016, 36(11): 1640-1647.
［18］尚可, 皮慧, 王友莲. 托珠单抗注射液治疗32例难治性活动性类风湿关节炎的临床观察［J］. 中华风湿病学杂志, 2015, 19(7): 451-454.
［19］Scott LJ. Tocilizumab: a review in rheumatoid arthritis ［J］. Drugs, 2017, 77(17): 1865-1879.
［20］Romano C, Del Mastro A, Sellitto A, et al. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients［J］. Clin Rheumatol, 2018, 37(6): 1695-1700.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	范杰, 金永明, 江孝龙, 蒋国华. lncRNA HOTAIR调控miR-206影响类风湿关节炎滑膜细胞增殖和凋亡的分子机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 736-742.
[4]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[5]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[6]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[7]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[8]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[9]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[10]	朱正怡, 倪映华, 高鹏, 王慧娟, 黄凌斐, 胡燕, 张莉雯, 杨巨飞, 方罗. 基于FAERS数据库的托珠单抗不良事件分析[J]. 中国临床药理学与治疗学, 2020, 25(8): 895-902.
[11]	赵倩，杨广，曹莉华，于陈宝. CNR1基因遗传变异对利拉鲁肽治疗早期2型糖尿病患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 182-188.
[12]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[13]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[14]	尹子毅，王峰，赵梦，张铁，王丕琳. 卡培他滨为基础一线方案治疗Her2阴性转移性乳腺癌的单中心回顾性研究及TYMP基因多态性分析[J]. 中国临床药理学与治疗学, 2019, 24(9): 1002-1008.
[15]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.

托珠单抗联合改善病情抗风湿药治疗中重度类风湿关节炎短期临床观察

Short-term clinical observation of moderate to severe active rheumatoid arthritis treated with tocilizumab combined with disease modifying antirheumatic drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价